Pertuzumab as first-line treatment of patients with metastatic HER2-positive breast cancer

Abstract

Present study confirmed the high efficacy of pertuzumab + trastuzumab added to standard chemotherapy as first-line or in neoadjuvanci. The treatment is safe, even in combination with an anthracycline.

Keywords

• Pertuzumab